QUANTITATIVE ASSESSMENT OF BETA-III TUBULIN EXPRESSION IN LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Beta-III tubulin (TUBB3) is a tumor-specific isoform of the microtubule protein beta-tubulin. TUBB3 is considered to be a marker of adverse prognosis and tumor resistance to therapy with taxanes and Vinka alkaloids. Association between TUBB3 expression and histological type of the tumor has not been studied properly yet. Objective. The expression level of TUBB3 in non-small cell lung cancer biopsy specimens has been measured on 2 groups of patients with adenocarcinoma and squamous cell carcinoma. Materials and methods. The samples with adenocarcinoma (n = 43) and squamous cell carcinoma (n = 39) were converted to suspension, filtered, fixed with 4 % formaldehyde, stained with monoclonal antibodies for TUBB3 and DyLight 650-conjugated secondary antibodies to mouse IgG and analyzed by flow-cytometry. The method was developed in N.N. Blokhin Russian Cancer Research Center. Results. The average level of TUBB3 expression in the adenocarcinoma group is higher than in the squamous cell carcinoma group (33.1 ± 12.4 % of cells expressing the marker in adenocarcinoma vs. 26.0 ± 13.6 % in squamous cell carcinoma; differences were statistically significant). The average level of TUBB3 expression in adenocarcinoma is 29.7 ± 8.1 % in female and is 34.9 ± 13.9 % in male (differences statistically insignificant). Since the group of patients with adenocarcinoma was presented by both men and women, while the group of patients with squamous cell carcinoma was only men, from the analysis was excluded all female patients. Differences between the groups remained statistically significant. Conclusion. TUBB3 expression in tumor tissue does not depend on the gender, at least among patients with adenocarcinoma of the lung, and at the same time, the level of TUBB3 in adenocarcinoma tissue is higher in comparison with squamous cell carcinoma tissue.

About the authors

M. M. Davydov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Author for correspondence.
Russian Federation

I. A. Mamichev

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Email: labmedchem@mail.ru
Russian Federation

E. A. Dudko

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

E. A. Bogush

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

V. Yu. Kirsanov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

B. E. Polotsky

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

M. I. Davydov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

T. A. Bogush

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.